Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 12, 2018- Will accelerate discovery of next-generation immunodementia therapeutics that go beyond A-beta and tau by targeting immune mechanisms identified by human genetics
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human...
Jun 11, 2018Eisai Inc. announced today the appointment of Lihua Yu, Ph.D., to President & Chief Data Sciences Officer, H3 Biomedicine, the cancer genomics based drug discovery company of Eisai. In her new...
-
Jun 5, 2018Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...
-
Jun 5, 2018RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
Jun 3, 2018-- First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally...